Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

GOLODIRSEN vs RISDIPLAM: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

GOLODIRSEN vs RISDIPLAM: Safety Overview

Metric GOLODIRSEN RISDIPLAM
Total FAERS Reports 406 3,619
Deaths Reported 5 336
Death Rate 1.2% 9.3%
Hospitalizations 53 719
Average Patient Age 15.0 yrs 21.8 yrs
% Female Patients 0.0% 55.2%
FDA Approval Date Dec 12, 2019 Aug 7, 2020
Manufacturer Sarepta Therapeutics, Inc. Genentech, Inc.
Route INTRAVENOUS ORAL
Marketing Status Prescription Prescription